Authors: Doyle, C Crump, M Pintilie, M Oza, AM

Citation: C. Doyle et al., Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer, J CL ONCOL, 19(5), 2001, pp. 1266-1274

Authors: Patnaik, A Warner, E Michael, M Egorin, MJ Moore, MJ Siu, LL Fracasso, PM Rivkin, S Kerr, I Litchman, M Oza, AM

Citation: A. Patnaik et al., Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors, J CL ONCOL, 18(21), 2000, pp. 3677-3689

Authors: Leung, PP Tannock, IF Oza, AM Puodziunas, A Dranitsaris, G

Citation: Pp. Leung et al., Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer, J CL ONCOL, 17(10), 1999, pp. 3082-3090

Authors: Patnaik, A Doyle, C Oza, AM

Citation: A. Patnaik et al., Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost, ANTI-CANC D, 9(10), 1998, pp. 869-878

Authors: Bjarnason, GA Cripps, C Goel, R Fine, S Oza, AM Skillings, JR Kerr, I Germond, CJ Moore, MJ Maroun, JA Franssen, E Dulude, H

Citation: Ga. Bjarnason et al., Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate,and long-term oral etoposide (FLAME) in unresectable or metastatic gastriccancer, AM J CL ONC, 21(6), 1998, pp. 537-542